
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important (ARGX)
bunhill argenx (NASDAQ:ARGX) preannounced Q4 2022 net sales of Vyvgart ahead of the JP Morgan Healthcare Conference in early January and provided a pipeline update with new indications for Vyvgart. Vyvgart’s momentum continued in the […]